Fundraising Fox

Third Pole

Waltham, US · Founded 2014 · Delaware corporation · 1 known investors

Third Pole Therapeutics develops a tankless, wearable inhaled nitric oxide (iNO) delivery platform, including the portable eNOfit device that generates nitric oxide on demand rather than storing it in tanks. The company operates in the biotech and medical device space, developing its technology through clinical feasibility studies for patient care.

Founders & leadership

EHElizabeth Holmberg
Elizabeth HolmbergCFO and Treasurer
BA
Basil AthensonChief Executive Officer and President
DZ
David ZapolNamed on SEC filing
EL
Emily Ladd-KravitzSecretary

Board

JMJeffrey McCormick
Jeffrey McCormickinBoard directorManaging Partner at Saturn Partners
WC
Werner CautreelsBoard director
RR
Ron RobisonBoard director
WH
William HeidenBoard director
HP
Hirak ParikhBoard director
AP
Ashleigh PalmerBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$85.8M disclosed across 3 rounds · 2015–2024

$16.9MraisedMar 2025 · 22 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Werner CautreelsDirector
  • David ZapolDirector
  • Emily Ladd-KravitzExecutive Officer
  • Elizabeth HolmbergExecutive Officer
  • Jeffrey McCormickDirector
  • Ron RobisonDirector
  • William HeidenDirector
  • Hirak ParikhDirector
  • Basil AthensonDirector, Executive Officer
Offering amount
$30M
Amount sold
$16.9M
Placement agents
Saturn Capital, Inc.
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$55.2MraisedFeb 2024 · 85 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Basil AthensonDirector, Executive Officer
  • Matthew GaylordDirector
  • Emily Ladd-KravitzExecutive Officer
  • Ron RobisonDirector
  • Elizabeth HolmbergExecutive Officer
  • Jeffrey McCormickDirector
  • Werner CautreelsDirector
  • William HeidenDirector
Amount sold
$55.2M
Placement agents
Saturn Capital, Inc.
First sale
Mar 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$13.8MraisedJan 2018 · 49 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ashleigh PalmerDirector
  • David ZapolExecutive Officer, Director, Promoter
  • Jeffrey McCormickDirector
Offering amount
$14M
Amount sold
$13.8M
Minimum investment
$15K
Sales commissions
$1.1M
Proceeds to insiders
$426K
Placement agents
Saturn Capital, Inc.
First sale
Dec 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$1.8M
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$3M
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$2M
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$1.5M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Third Pole do?
Third Pole Therapeutics develops a tankless, wearable inhaled nitric oxide (iNO) delivery platform, including the portable eNOfit device that generates nitric oxide on demand rather than storing it in tanks. The company operates in the biotech and medical device space, developing its technology through clinical feasibility studies for patient care.
Who are Third Pole's investors?
Third Pole's investors include Saturn Partners.
How much funding has Third Pole raised?
Third Pole has disclosed $85.8M raised across 3 rounds.
Where is Third Pole headquartered?
Third Pole is headquartered in Waltham, US.